Nestlé S.A. (NSRGF)
| Previous Close | 108.48 |
| Open | 106.81 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 106.25 - 109.38 |
| 52 Week Range | 103.75 - 143.92 |
| Volume | |
| Avg. Volume | 13,488 |
| Market Cap | 296.295B |
| Beta (5Y Monthly) | 0.26 |
| PE Ratio (TTM) | 17.65 |
| EPS (TTM) | 6.03 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.00 (2.77%) |
| Ex-Dividend Date | Apr 11, 2022 |
| 1y Target Est | N/A |
- The Guardian
Quality Street axes plastic wrappers for recyclable paper
Nestlé says change after 86 years will keep 2bn wrappers a year out of landfill
- Bloomberg
Nestlé Says It Will Drop Palm Oil Supplier Accused of Abuses
(Bloomberg) -- Nestlé SA has pledged to cut ties with an Indonesian palm oil supplier accused of land-rights abuses and environmental harm.Most Read from BloombergMacKenzie Scott Files for Divorce From Science Teacher HusbandMeta to Cut Headcount for First Time, Slash Budgets Across TeamsStocks Plummet to 22-Month Low as Fed Hawks Circle: Markets WrapTrump Refuses to Delay Florida Deposition in Phone-Fraud Case Despite HurricaneTop Apple Executive Is Leaving After Making Crude Remarks in TikTok
- GlobeNewswire
Cerecin closes Series IIB financing to advance CER-0001 clinical programs and build pipeline in neuro-metabolism drug development
Series IIB Financing was supported by existing and new investors in South Korea.Proceeds strengthen Cerecin’s operating position to advance the clinical studies of CER-0001 in migraine and infantile spasms.New funds will also be used to build Cerecin’s pipeline and advance plans for a pivotal trial in Alzheimer’s disease. SINGAPORE and DENVER, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cerecin Inc., a clinical-stage biotechnology company pioneering innovative neurotherapeutics, today announced it has su
